Welcome!
Singapore Medical Group (SMG)
Broker's Calls
SMG should be valued closer to Singapore O&G's offer, says UOB Kay Hian; shareholders should 'reject offer'
"Armed with better overseas exposures in Vietnam Indonesia and Australia, we think there could be potential upside to SMG’s offer"
September 22, 2022
Offer
SMG’s CEO, non-executive chairman and executive director make 37 cents per share privatisation bid for company
The cash price is a premium of 18.1% over the one-month VWAP of SMG's shares traded on the SGX.
September 13, 2022
Broker's Calls
Record revenue and growth prospects makes Singapore Medical Group a 'buy' : UOBKH
A TP of 45 cents gives the counter a 45.5% upside from its 33 cent call
August 04, 2021
Results
Singapore Medical Group posts record 1H21 earnings of $7.2 mil
SMG reported an all-time high in half-yearly revenue of $49.7 mil for the period.
August 03, 2021
Results
SMG reports record 1Q21 revenue and net profit on higher diagnostic & aesthetics business
The group also posted its first share of profits of JV entities and associates, reversing from its loss in the year before.
May 10, 2021
Results
Singapore Medical Group reports 36.1% lower FY20 earnings of $8.7 mil
The group has recommended a final dividend of 0.4 cents per share for the FY2020, the same as FY2019.
February 19, 2021
Broker's Calls
UOBKH ups Singapore Medical Group's TP on 'attractive' valuation
UOB Kay Hian is maintaining its “buy” call on private specialist and healthcare services provider Singapore Medical Group,
January 11, 2021
Results
Singapore Medical Group reports 49.5% lower earnings of $3.5 mil for 1H20
Singapore Medical Group (SMG) posted 49.5% lower earnings of $3.5 million for 1H20 ended June, from the $6.8 million registered a year ago due to the “challenging market conditions”, and lower number of medical tourists.
August 06, 2020
Broker's Calls
KGI starts Singapore Medical Group at 'outperform' on diverse network of specialist healthcare services
KGI Securities has initiated coverage on Singapore Medical Group (SMG) with an “outperform” call and target price of 34 cents, which represents a total upside of 39.0%, including a forecasted dividend yield of 1.4% for FY21F.
July 08, 2020
Broker's Calls
Singapore Medical Group kept on 'neutral' as uncertainties loom
Singapore Medical Group kept on 'neutral' as uncertainties loom
May 27, 2020